Skip to main content

Table 1 Patient characteristics (n = 92)

From: Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study

  Variables  
Age (year, mean ± SD)   65.9 ± 9.4
Sex Male 72 (78.3%)
  Female 20 (21.7%)
Siewert classification Type I adenocarcinoma 2 (2.2%)
  Type II adenocarcinoma 16 (17.4%)
  Type III adenocarcinoma 11 (12.0%)
  Not applicable 63 (68.5%)
Macro type Type 0 36 (39.1%)
  Type 1 4 (4.3%)
  Type 2 26 (28.3%)
  Type 3 21 (22.8%)
  Type 4 1 (1.1%)
  Type 5 4 (4.3%)
Preoperative chemotherapy No 79 (85.9%)
  Yes 13 (14.1%)
Extent of surgical resection Subtotal esophagectomy with partial gastrectomy 14 (15.2%)
  Proximal gastrectomy with partial esophagectomy 30 (32.6%)
  Total gastrectomy with partial esophagectomy 48 (52.2%)
Extent of lymph node dissection Abdominal, mediastinal and cervical 11 (12.0%)
  Abdominal and mediastinal 9 (9.8%)
  Abdominal and lower mediastinal 27 (29.3%)
  Abdominal 45 (48.9%)
Pathological tumor size (mm, mean ± SD)   46.1 ± 23.7
Main histologic type Adenocarcinoma 79 (85.9%)
  Squamous-cell carcinoma 13 (14.1%)
Lymphatic invasion L0 32 (34.8%)
  L1 60 (65.2%)
Venous invasion V0 32 (34.8%)
  V1–2 60 (65.2%)
Pathological depth of tumor invasion pT1 33 (35.9%)
  pT2 11 (12.0%)
  pT3 35 (38.0%)
  pT4 13 (14.1%)
Lymph node metastasis pN0 47 (51.1%)
  pN1 19 (20.7%)
  pN2 14 (15.2%)
  pN3 12 (13.0%)
Distant metastasis pM0 72 (78.3%)
  pM1 20 (21.7%)
TNM stage pStage I 36 (39.1%)
  pStage II 19 (20.7%)
  pStage III 17 (18.5%)
  pStage IV 20 (21.7%)
Adjuvant chemotherapy No 43 (46.7%)
  Yes 49 (53.3%)
  1. Including lower thoracic paraesophageal, diaphragmatic and posterior mediastinal lymph node.